Karyopharm Therapeutics (NASDAQ:KPTI) Lowered to Hold Rating by StockNews.com

StockNews.com downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research report released on Wednesday morning.

Several other research firms have also recently weighed in on KPTI. Robert W. Baird dropped their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Finally, Piper Sandler lifted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI traded up $0.02 during mid-day trading on Wednesday, hitting $0.91. 230,098 shares of the stock were exchanged, compared to its average volume of 1,263,632. The stock has a market capitalization of $112.97 million, a price-to-earnings ratio of -0.75 and a beta of 0.16. The firm’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.91. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the business posted ($0.30) earnings per share. On average, analysts predict that Karyopharm Therapeutics will post -0.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $494,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $167,000. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $31,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $143,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).